Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (5)

2019

  1. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 107, pp. 186-195

2006

  1. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

    International Journal of Gynecological Cancer, Vol. 16, Núm. 1, pp. 71-76

2005

  1. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532

2002

  1. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research

    Gynecologic Oncology, Vol. 84, Núm. 2, pp. 201-209

  2. The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research

    Cancer, Vol. 95, Núm. 7, pp. 1605-1610